Authors

    Language

    English

    Publication Date

    3-1-2021

    Journal

    Cancer Research

    DOI

    10.1158/0008-5472.CAN-20-3691

    PMID

    33355186

    PMCID

    PMC8026656

    PubMedCentral® Posted Date

    9-1-2021

    PubMedCentral® Full Text Version

    Author MSS

    Abstract

    Patients with cancer are more susceptible to be infected by SARS-CoV-2 and develop severe outcomes including ICU admittance, mechanical ventilator support, and a high rate of mortality. Like mid-to late-stage cancer, SARS-CoV-2 infection is associated with platelet hyperactivity, systemic inflammation, thrombotic complications, and coagulopathy. Platelets also promote cancer cell growth, survival in circulation, and angiogenesis at sites of metastases. In this article, we will discuss the potential for platelets in the development of systemic inflammation and thrombosis in SARS-CoV-2-infected patients with cancer, with the concern that the platelet-induced pathogenic events are likely magnified in cancer patients with COVID-19.

    Keywords

    Blood Platelets, COVID-19, Humans, Inflammation, Neoplasms, Platelet Activation, Risk Assessment, Risk Factors, SARS-CoV-2, Thrombosis

    Published Open-Access

    yes

    Share

    COinS
     
     

    To view the content in your browser, please download Adobe Reader or, alternately,
    you may Download the file to your hard drive.

    NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.